PARP1 and ovarian carcinoma: In line, using ovarian cancer cell line data from the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity Consortium (GDSC)40, we found that PHGDH-low expressing ovarian cancer cell lines were more resistant to the PARP inhibitor olaparib (Fig. 6e).